References of "Kolh, Philippe"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailDoing better in more complex patients: leading the way for QUIP.
Osnabrugge, Ruben L.; Kappetein, A. Pieter; Head, Stuart J. et al

in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2016), 49(2), 397-8

Detailed reference viewed: 22 (4 ULg)
Full Text
Peer Reviewed
See detailThe radial artery for coronary artery bypass grafting: a second revival?
Sousa Uva, Miguel; Kolh, Philippe ULg

in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2016), 49(1), 210-1

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailMethodology manual for European Association for Cardio-Thoracic Surgery (EACTS) clinical guidelines.
Sousa-Uva, Miguel; Head, Stuart J.; Thielmann, Matthias et al

in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2015), 48(6), 809-16

The goal of all clinical guidelines is to assist patients and practitioners in making healthcare decisions. However, clinical guidelines have been questioned about their quality, transparency and ... [more ▼]

The goal of all clinical guidelines is to assist patients and practitioners in making healthcare decisions. However, clinical guidelines have been questioned about their quality, transparency and independence. Based on the revision of manuals by other scientific cardiothoracic organizations, this document provides instructions for the development of European Association for Cardio-Thoracic Surgery (EACTS) clinical guidelines and other types of evidence-based documents. Four key areas have been addressed: (i) selection of taskforce members and transparency of relations with the industry, (ii) methods for critical appraisal of medical evidence, (iii) rules for writing recommendations and (iv) review process. It is hoped that, by adopting this methodology, clinical guidelines produced by the EACTS will be well balanced, objective and, importantly, trusted by physicians and patients who benefit from their implementation. [less ▲]

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailStructure and functioning of the Heart Team: primum non nocere.
Stefanini, Giulio G.; Kolh, Philippe ULg

in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2015), 48(4), 529-30

Detailed reference viewed: 19 (1 ULg)
Full Text
Peer Reviewed
See detailAnalysis of on-pump and off-pump surgery in the Arterial Revascularization Trial.
Poullis, Michael; Kolh, Philippe ULg

in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2015), 47(6), 1065

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailEditor's Choice - Management of Chronic Venous Disease: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS).
Wittens, C.; Davies, A. H.; Baekgaard, N. et al

in European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery (2015), 49(6), 678-737

Detailed reference viewed: 18 (0 ULg)
Full Text
Peer Reviewed
See detailPerspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization : Fifty Years of Revascularization: Where Are We and Where Are We Heading?
Costa, Francesco; Ariotti, Sara; Valgimigli, Marco et al

in Journal of cardiovascular translational research (2015), 8(4), 211-20

The joint European Society of Cardiology and European Association of Cardio-Thoracic Surgery (ESC/EACTS) guidelines on myocardial revascularization collect and summarize the evidence regarding decision ... [more ▼]

The joint European Society of Cardiology and European Association of Cardio-Thoracic Surgery (ESC/EACTS) guidelines on myocardial revascularization collect and summarize the evidence regarding decision-making, diagnostics, and therapeutics in various clinical scenarios of coronary artery disease, including elective, urgent, and emergency settings. The 2014 document updates and extends the effort started in 2010, year of the first edition of these guidelines. Importantly, this latest edition provides a systematic review of all randomized clinical trials performed since 1980, comparing different strategies of myocardial revascularization, including coronary artery bypass graft (CABG), balloon angioplasty, percutaneous coronary intervention (PCI) with bare-metal stents (BMS) and first- and second-generation drug-eluting stents (DES). This review aims to highlight the most relevant novelties introduced by the 2014 edition of the ESC/EACTS myocardial revascularization guidelines as compared with the previous edition and to describe similarities and differences with the American societies' guidelines. [less ▲]

Detailed reference viewed: 19 (0 ULg)
Full Text
Peer Reviewed
See detailBilateral internal thoracic artery use: will another retrospective study ever strengthen the prospect?
Head, Stuart J.; Kappetein, A. Pieter; Kolh, Philippe ULg

in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2015), 47(4), 709

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailTrans-Atlantic differences in coronary artery bypass grafting: is it the patient, the surgery or the health-care system?
Uva, Miguel Sousa; Kolh, Philippe ULg

in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2015), 47(4),

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detail2014 ESC/EACTS guidelines on myocardial revascularization.
Windecker, Stephan; Kolh, Philippe ULg; Alfonso, Fernando et al

in Revista espanola de cardiologia (English ed.) (2015), 68(2), 144

Detailed reference viewed: 18 (0 ULg)
Full Text
Peer Reviewed
See detailNew biomarkers for primary mitral regurgitation.
Deroyer, Céline ULg; Magne, Julien; Moonen, Marie ULg et al

in Clinical proteomics (2015), 12

BACKGROUND: Mitral regurgitation is a frequent valvular heart disease affecting around 2.5 % of the population with prevalence directly related to aging. Degeneration of mitral valve is broadly considered ... [more ▼]

BACKGROUND: Mitral regurgitation is a frequent valvular heart disease affecting around 2.5 % of the population with prevalence directly related to aging. Degeneration of mitral valve is broadly considered as a passive ongoing pathophysiological process and little is known about its physiological deregulation. The purpose of this study was to highlight new biomarkers of mitral regurgitation in order to decipher the underlying pathological mechanism as well as to allow the diagnosis and the monitoring of the disease. RESULTS: Modulation of various blood proteins expression was examined in patients suffering from different grades of mitral regurgitation (mild, moderate and severe) compared to healthy controls. To this end, several routine clinical assays and the multi analyte profile technology targeting 184 proteins were used. High-density lipoprotein, apolipoprotein-A1, haptoglobin and haptoglobin-alpha2 chain levels significantly decreased proportionally to the degree of mitral regurgitation when compared to controls. High-density lipoprotein and apolipoprotein-A1 levels were associated with effective regurgitant orifice area and regurgitant volume. Apolipoprotein-A1 was an independent predictor of severe mitral regurgitation. Moreover, with ordinal logistic regression, apolipoprotein-A1 remained the only independent factor associated with mitral regurgitation. In addition, myxomatous mitral valves were studied by immunocytochemistry. We observed an increase of LC3, the marker of autophagy, in myxomatous mitral valves compared with healthy mitral valves. CONCLUSION: These potential biomarkers of mitral regurgitation highlighted different cellular processes that could be modified in myxomatous degenerescence: reverse cholesterol transport, antioxidant properties and autophagy. [less ▲]

Detailed reference viewed: 48 (11 ULg)
Full Text
Peer Reviewed
See detailImpact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis.
Siller-Matula, Jolanta M.; Petre, Alexandra; Delle-Karth, Georg et al

in European heart journal. Acute cardiovascular care (2015)

OBJECTIVE: To review systematically the evidence and perform a meta-analysis of benefits and risks associated with use of P2Y12 receptor inhibitors in coronary artery bypass graft-, non-cardiac- and ... [more ▼]

OBJECTIVE: To review systematically the evidence and perform a meta-analysis of benefits and risks associated with use of P2Y12 receptor inhibitors in coronary artery bypass graft-, non-cardiac- and device surgery. DATA SELECTION AND ANALYSIS: We performed a meta-analysis of published studies. Patients with preoperative use of clopidogrel, ticagrelor or prasugrel (late discontinuation: <5 days before surgery or no discontinuation) were compared with patients without preoperative use of the respective drug (early discontinuation: 5 days before surgery or no users of P2Y12 receptor inhibitors). Outcomes evaluated were re-operation for major bleeding, death, myocardial infarction, combined major adverse cardiac events (MACEs) and major haematoma. Using a random effect model, relative risks (RRs) and 95% confidence intervals (CI) were calculated for each outcome. RESULTS: Fifty-four studies met the selection criteria and included 50,048 patients. Preoperative use of clopidogrel on top of aspirin in patients undergoing coronary artery bypass graft was associated with a 2.5-fold increased risk of re-operation for bleeding (95% CI: 1.92-3.25; p<0.001) and a 1.47-fold increased risk of death (95% CI: 1.25-1.72; p<0.001), but did not diminish the risk for myocardial infarction (RR: 0.96; 95% CI: 0.75-1.25; p=0.18) or MACE (RR: 1.16; 95% CI: 0.90--1.50; p=0.30). In patients undergoing non-cardiac surgery, preoperative use of clopidogrel increased the RR of re-operation for major bleeding by 2.05-fold (95% CI: 1.13-3.73; p=0.002) but did not reduce the RR for MACE or death. Clopidogrel use during cardiac device implantation raised the RR for procedure-related haematoma by 3.0-fold (95% CI: 1.30--6.94; p=0.001). Whereas preoperative ticagrelor use did not increase the risk for mortality (RR: 1.03; 95% CI: 0.49-2.14), preoperative prasugrel use tended to increase the risk for death (RR: 5.06; 95% CI: 0.54-47.65). CONCLUSION: Preoperative exposure to clopidogrel on top of aspirin did not reduce the risk of MACE but was associated with increased risk of bleeding and mortality. [less ▲]

Detailed reference viewed: 17 (1 ULg)
Full Text
Peer Reviewed
See detailBilateral internal thoracic artery grafts for myocardial revascularization in insulin-dependent diabetic patients: time for wide clinical practice?
Jatene, Fabio Biscegli; Kolh, Philippe ULg

in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2015), 48(1), 121-2

Detailed reference viewed: 15 (0 ULg)
Full Text
Peer Reviewed
See detailSurgical or percutaneous revascularization for isolated left anterior descending stenoses: are we in the same boat?
Stefanini, Giulio; Windecker, Stephan; Kolh, Philippe ULg

in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2015)

Detailed reference viewed: 11 (3 ULg)
Full Text
Peer Reviewed
See detail2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
Elliott, Perry M.; Anastasakis, Aris; Borger, Michael A. et al

in European heart journal (2014), 35(39), 2733-79

Detailed reference viewed: 18 (0 ULg)